Find information on thousands of medical conditions and prescription drugs.

Myasthenia gravis

Myasthenia gravis (MG, Latin: "grave muscle weakness") is a neuromuscular disease leading to fluctuating weakness and fatiguability. It is one of the best known autoimmune disorders and the antigens and disease mechanisms have well been identified. Weakness is caused by circulating antibodies that block acetylcholine receptors at the post-synaptic neuromuscular junction, inhibiting the stimulative effect of the neurotransmitter acetylcholine. Myasthenia is treated with immunosuppression and cholinesterase inhibitors. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
Mac Ardle disease
Macroglobulinemia
Macular degeneration
Mad cow disease
Maghazaji syndrome
Mal de debarquement
Malaria
Malignant hyperthermia
Mallory-Weiss syndrome
Malouf syndrome
Mannosidosis
Marburg fever
Marfan syndrome
MASA syndrome
Mast cell disease
Mastigophobia
Mastocytosis
Mastoiditis
MAT deficiency
Maturity onset diabetes...
McArdle disease
McCune-Albright syndrome
Measles
Mediterranean fever
Megaloblastic anemia
MELAS
Meleda Disease
Melioidosis
Melkersson-Rosenthal...
Melophobia
Meniere's disease
Meningioma
Meningitis
Mental retardation
Mercury (element)
Mesothelioma
Metabolic acidosis
Metabolic disorder
Metachondromatosis
Methylmalonic acidemia
Microcephaly
Microphobia
Microphthalmia
Microscopic polyangiitis
Microsporidiosis
Microtia, meatal atresia...
Migraine
Miller-Dieker syndrome
Mitochondrial Diseases
Mitochondrial...
Mitral valve prolapse
Mobius syndrome
MODY syndrome
Moebius syndrome
Molluscum contagiosum
MOMO syndrome
Mondini Dysplasia
Mondor's disease
Monoclonal gammopathy of...
Morquio syndrome
Motor neuron disease
Motorphobia
Moyamoya disease
MPO deficiency
MR
Mucopolysaccharidosis
Mucopolysaccharidosis...
Mullerian agenesis
Multiple chemical...
Multiple endocrine...
Multiple hereditary...
Multiple myeloma
Multiple organ failure
Multiple sclerosis
Multiple system atrophy
Mumps
Muscular dystrophy
Myalgic encephalomyelitis
Myasthenia gravis
Mycetoma
Mycophobia
Mycosis fungoides
Myelitis
Myelodysplasia
Myelodysplastic syndromes
Myelofibrosis
Myeloperoxidase deficiency
Myoadenylate deaminase...
Myocarditis
Myoclonus
Myoglobinuria
Myopathy
Myopia
Myositis
Myositis ossificans
Myxedema
Myxozoa
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles such as those that control eye and eyelid movement, facial expression, chewing, talking, and swallowing are often, but not always, involved in the disorder. The muscles that control breathing and neck and limb movements can also be affected.

Although myasthenia gravis may affect any voluntary muscle, muscles that control eye and eyelid movement, facial expression, and swallowing are most frequently affected. The onset of the disorder may be sudden or rapid. Symptoms often are not immediately recognized as myasthenia gravis; a proportion only receives a diagnosis after more than a year.

In most cases, the first noticeable symptom is weakness of the eye muscles. In others, difficulty in swallowing and slurred speech may be the first signs. The degree of muscle weakness involved in myasthenia gravis varies greatly among patients, ranging from a localized form, limited to eye muscles (ocular myasthenia), to a severe or generalized form in which many muscles - sometimes including those that control breathing - are affected. Symptoms, which vary in type and severity, may include asymmetrical ptosis (a drooping of one or both eyelids), diplopia (blurred or double vision) due to weakness of the muscles that control eye movements, unstable or waddling gait, weakness in arms, hands, fingers, legs, and neck, a change in facial expression, dysphagia (difficulty in swallowing) and shortness of breath, and dysarthria (impaired speech, often nasal due to weakness of the pharyngeal muscles).

A myasthenic crisis may give rise to a generalized paralysis, including those of the respiratory muscles, and assisted ventilation may be required to sustain life. In patients whose respiratory muscles are already weak, crises may be triggered by infection, fever, an adverse reaction to medication, or emotional stress (Bedlack & Sanders 2000).

Diagnosis

Myasthenia can be a difficult diagnosis, as the symptoms can be subtle and hard to distinguish from both normal variants and other neurological disorders (Scherer et al 2005).

A thorough physical examination can reveal easy fatiguability, with the weakness improving after rest and worsening again on repeat of the exertion testing. Applying ice to the weak muscle groups may characteristically improve the weakness.

Blood tests

If the diagnosis is suspected, serology can be performed in a blood test to identify antibodies against the acetylcholine receptor. The test has a reasonable sensitivity of 80-96%, but in MG limited to the eye muscles (ocular myasthenia) the test may be negative in up to 50% of the cases. Often, parallel testing is performed for Lambert-Eaton myasthenic syndrome, in which other antibodies (against a voltage-gated calcium channel) are frequently found.

Read more at Wikipedia.org


[List your site here Free!]


Potential bromide toxicity associated with Myasthenia gravis treatment in a 22 month old child
From CHEST, 10/1/05 by Aaron J. Godshall

INTRODUCTION: Treatment strategies for Myasthenia gravis (MG) are directed at reducing acetylcholine receptor antibody production (immunosuppression, thymectomy, corticosteroids) and increasing availability of acetylcholine at the neuromuscular junction with acetylcholinesterase inhibitors. Pyridostigmine bromide (PB) is an acetylcholinesterase inhibitor used to treat MG. Toxicity from PB overdose has focused on cholinergic toxicity, but bromide toxicity (bromism) can be underappreciated. We present one of the first reported pediatric cases suspicious for bromism from PB use.

CASE PRESENTATION: A 22-month-old male with a history of MG presented to the emergency department with bradycardia and respiratory distress. He was in his usual state of health and feeding normally at home when he developed increased salivation and difficulty breathing. There was no report of choking or coughing surrounding the dyspnea. At home when he became ashen, emergency medical services was activated and CPR was initiated. Upon arrival, paramedics noted bradycardia and respiratory arrest. On hospital presentation, he was bradycardic (pulse = 30), breathing shallow and had a Glasgow Coma Scale score of 3. There was no evidence of increased lacrimation, excessive urination, miosis, diarrhea, nor emesis. He was intubated after receiving atropine, etomidate and rocuronium. Heart rate increased transiently after intubation; however, bradycardia returned after 30 minutes. A chemistry panel revealed an elevated chloride level of 121 mEq/L with a low anion gap of 3. A bromide level obtained two days after presentation was elevated at 14 mg/dL (normal <0.5 mg/dL). Clinical course was significant for 3 days of persistent CNS depression. Head CT was within normal limits. Past medical history was significant for MG diagnosed 5 months prior to admission for persistent ptosis and difficulty holding his head upright. His evaluation included an abnormal tensilon test and an elevated" serum acetylcholine receptor antibody titer. PB therapy was initiated with partial improvement in weakness and ptosis. Thymectomy was performed 2 months prior to admission. Due to persistent symptoms, PB doses were increased independently by ophthalmology and neurology.

DISCUSSIONS: Signs of cholinergic toxicity include diarrhea, excessive

urination, miosis, bradycardia, emesis, lacrimation and salivation. Our patient displayed two of these, but also displayed evidence of CNS depression; a sign not typically associated with cholinergic crisis. Furthermore, pyridostigmine does not readily cross the blood Drain barrier, thus raising concerns for another factor to account for the CNS depression. Our suspicion for bromism stemed from the high chloride level of 121 mEq/L with a low anion gap. Many hospital laboratories utilize electrolyte panels that interpret halide ions as chloride; therefore, an elevated bromide level would be falsely reported as an elevated chloride level. If we approximate a normal chloride level of 110 mEq/L then 11 mEq of Bromide could be present. This level translates into a toxic level of 88 mg/dL (toxic level > 50 mg/dL). Unfortunately, a specific bromide level was not measured until after two days of resuscitation with normal saline and maintenance of brisk urine output, maneuvers that increase excretion of bromide. Bromism has previously been associated with pyridostigmine [1]. To our knowledge, this is the first reported suspicious case occurring in a child. In cases of long-term exposure to PB, such as treatment for MG, bromism should be considered in the differential diagnosis; especially when the clinical picture is not one of typical cholinergic toxicity. Clinical suspicion and prompt laboratory confirmation can assist in establishing inpatient treatment plan and on-going pyridostigmine treatment. Other agents are available that are not complexed with bromide and may present a viable alternative.

CONCLUSION: Bromide toxicity should be considered in patients on PB who present with depressed mental status.

REFERENCE:

[1] Rothenberg, D.M., et al., Bromide intoxication secondary to pyridostigmine bromide therapy. Jama, 1990. 263(8): p. 1121-2.

DISCLOSURE: Aaron Godshall, None.

Aaron J. Godshall MD * Cyrus Rangan MD John T. Li MD Childrens Hospital Los Angeles, Long Beach, CA

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Myasthenia gravis
Home Contact Resources Exchange Links ebay